Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
- 2023
-
1. Planning and response to COVID-19: lessons from China and South-East Asia
- Prof. Annelies Wilder-Smith
- 2022
-
2. The emergence of the SARS-CoV-2 Omicron variant
- Prof. Emma Thomson
-
3. How is Omicron different?
- Prof. Emma Thomson
- 2021
-
5. Potential of ‘long-COVID’ in triggering chronic co-pathologies
- Dr. İmdat Eroğlu
-
6. SARS-CoV-2 monoclonal antibody testing in vivo
- Prof. Michael Diamond
-
7. mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals
- Prof. E. John Wherry
-
8. SARS-CoV-2 variants: implications for immunity and vaccine development
- Prof. Danny Altmann
-
10. SARS-COV-2 human monoclonal antibody therapy update
- Prof. James Crowe
-
11. Emergence of blood clotting disorders resulting from COVID vaccines inoculations
- Prof. Dr. Sabine Eichinger
-
12. SARS-CoV-2 evolution within and between individuals
- Prof. Katia Koelle
-
13. Identifying SARS-CoV-2 proteases
- Prof. Dr. Christa E. Müller
- Prof. Dr. Michael Gütschow
-
14. Genetic surveillance and the emergence of SARS-CoV-2 variants
- Prof. Emma Thomson
-
15. The COVID-19 outbreak: April 2021 update
- Prof. Jonathan Temte
-
16. ABO blood groups and SARS-CoV-2 susceptibility
- Dr. Sean Stowell
-
17. Impact of COVID-19 on neuropsychiatric disorders and mental health
- Prof. Anthony David
-
18. The immune system response to the SARS-CoV-2 virus: March 2021 update
- Prof. Paul Klenerman
-
23. SARS-CoV-2 vaccine rollout campaigns
- Prof. Luis Graca
-
25. Interspecies transmission of SARS-CoV-2
- Dr. Dalan Bailey
-
26. Complement activation in COVID-19
- Prof. Jeffrey Laurence
-
27. Human movement patterns and local spread of COVID-19
- Prof. Ben Cowling
-
28. SARS-CoV-2 mutations: phenotypes and implications for vaccine development
- Prof. David Montefiori
- 2020
-
29. The immune system response to the SARS-CoV-2 virus: December 2020 update
- Prof. Paul Klenerman
-
30. Triage and end of life care planning in COVID-19
- Prof. Robin Taylor
-
31. Natural killer cells as COVID-19 therapy
- Dr. Philippa Kennedy
-
32. Update on the SNG001 drug, an INFβ therapy for COVID-19
- Prof. Stephen Holgate
-
34. Identification of a new coronavirus-specific RNA export protein complex
- Dr. Montse Bárcena-Martin
-
35. The neurological symptoms of COVID-19
- Dr. Michael Zandi
-
36. Imperial College London’s saRNA Vaccine - COVAC1
- Dr. Katrina Pollock
-
37. Interferon-α2b as a therapy for COVID-19
- Prof. Eleanor N. Fish
-
38. Potential long-term health effects of a SARS-CoV-2 infection
- Prof. Danny Altmann
-
39. The COVID-19 coronavirus outbreak: October 2020 update
- Prof. Jonathan Temte
-
41. Rheumatic diseases and COVID-19
- Dr. Zachary Wallace
-
42. The cardiovascular complications of SARS-CoV-2 infection
- Prof. Srihari Naidu
-
43. Medical wearable devices for tracking symptoms of COVID-19
- Prof. John Rogers
-
44. Risk of re-emergence of COVID-19 after exit from lockdown
- Dr. Leonardo Lopez
-
45. The evolutionary origin of SARS-CoV-2
- Dr. Feng Gao
-
46. Predicting COVID-19 outbreaks by measuring SARS-CoV-2 RNA in sewage sludge
- Prof. Jordan Peccia
-
47. Approaches for elucidating genetic susceptibility to SARS-CoV-2
- Dr. Kenneth Baillie
-
48. The immune system response to the SARS-CoV-2 virus: July 2020 update
- Prof. Paul Klenerman
-
49. The impact of COVID-19 in the elderly and in care homes
- Dr. David Strain
-
50. Human challenge trials for vaccines against COVID-19
- Prof. Peter Smith
-
51. The development of SARS-CoV-2 vaccines
- Prof. Peter Hotez
-
52. Convalescent plasma therapy as a treatment for COVID-19
- Dr. Manu Shankar-Hari
-
53. Remdesivir COVID-19 clinical trial
- Prof. Mahesh Parmar
-
54. Nanotechnologies in the fight against coronaviruses
- Prof. Sabine Szunerits
-
55. The COVID-19 coronavirus outbreak: May 2020 update
- Prof. Jonathan Temte
-
56. INFβ therapy for COVID-19: the new SNG001 drug
- Prof. Stephen Holgate
-
57. Strategies for exiting the lockdown
- Prof. David McCoy
-
58. SARS-CoV-2 human monoclonal antibody therapy
- Prof. James Crowe
-
59. An FDA approved salivary test for SARS-CoV-2 infection
- Prof. Andrew Brooks
-
60. Development of an intranasal vaccine for SARS-CoV-2
- Dr. Scot Roberts
-
61. The immune system response to the SARS-CoV-2 virus: an update
- Prof. Paul Klenerman
-
62. A novel AIOD-CRISPR system for diagnosis of SARS-CoV-2
- Prof. Changchun Liu
-
63. Development of PRO-140 (Leronlimab) as a treatment for COVID-19
- Dr. Jacob Lalezari
-
64. COVID-19 epidemiology and potential treatments: follow up interview
- Prof. Ralph Baric
-
65. SARS-CoV-2 vaccine development: where are we now?
- Prof. Gary Kobinger
-
66. SARS-CoV-2: What we need to know and possible future therapies
- Prof. Stanley Perlman
-
67. SARS-CoV-2 vaccine: current biological targets and considerations
- Dr. Adolfo Garcia-Sastre
-
68. The current understanding of the biology of the SARS-CoV-2 virus
- Prof. Peter Palese
-
70. The immune system response to the SARS-CoV-2 virus
- Prof. Paul Klenerman
-
71. SARS-CoV-2 vaccine development
- Prof. Stanley Plotkin
-
72. The COVID-19 outbreak: an update on the SARS-CoV-2 virus
- Prof. Ralph Baric
-
73. The COVID-19 coronavirus outbreak: a current view
- Prof. Jonathan Temte
-
74. The COVID-19 coronavirus outbreak: March 2020 update
- Prof. Jonathan Temte
Topics Covered
- COVID-19
- SARS
- Community compliance
- Healthcare infrastructure
- Epidemic preparedness
- Public health
- Community buy-in
- History of epidemic
- Trust
- Contact tracing
- Reporting
- Disease burden
- Communication strategy
- Social media
- Top-down approach
- Leadership
- Herd immunity
- WHO
Biography
Annelies Wilder-Smith is Professor of Emerging Infectious Diseases at the London School of Hygiene and Tropical Medicine, and visiting Professor at the Lee Kong Chian School of Medicine, Singapore. She also serves as Consultant to the Initiative of Vaccine Research at the World Health Organization, Geneva, Switzerland. She is the Past President of the International Society of Travel Medicine (ISTM), and Past-President of the Asia Pacific Society of Travel Medicine.
Her special research interests include travel health, vaccine preventable and emerging infectious diseases, in particular dengue, Zika, yellow fever, chikgununya, influenza and meningococcal disease. With a career spanning almost three decades, she has led and co-led various clinical trials, published more than 280 scientific papers, edited and co-edited textbooks and travel medicine books, served on various editorial boards and scientific committees, including being editorial consultant to The Lancet. Her awards include the Myrone Levine Vaccinology Prize, the Honor Group Award for exemplary leadership and coordination in determining and communicating global yellow fever risk presented at the CDC Award Ceremony, the Mercator Professorship award by the German Research Foundation and the Ashdown Oration Award by the Australian College of Travel Medicine. She is the Principal Investigator of an EU funded international consortium called “ZikaPLAN,” and recently completed another 4 year research project on dengue, also funded by the European Commission.
Professor Wilder Smith obtained her MD from the University of Heidelberg, Germany, in 1987, her Master in International Health from Curtin University in Australia, and her PhD from the University of Amsterdam, The Netherlands, in 2003. The topic of her PhD was on “W135 meningococcal disease in Hajj pilgrims”. Over the past 15 years she has developed and taught courses in global health, communicable diseases and travel medicine both in Singapore and beyond. She worked and lived in the Asia Pacific region for more than 18 years (China, Nepal, Papua New Guinea and since 1998 in Singapore). From 2011-2012, she was the Director of Master Programme in International Health at the Institute of Public Health, University of Heidelberg, Germany.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Wilder-Smith, A. (2023, May 16). Planning and response to COVID-19: lessons from China and South-East Asia [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 8, 2023, from https://hstalks.com/bs/5312/.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Annelies Wilder-Smith has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.